Cortiment® MMX Pharmacokinetic Study

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-09-25. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: negativewomendiabetesdementiahours
  Phrases that lowered it: healthylabeland safetysubjectspharmacokinetic
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Primary purpose: other (lowers risk) · Design
• Sponsor's past termination rate: 10.9% (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 60.3% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 6.5% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Blinding: none (lowers risk) · Design
• Sponsor's past trials: 138 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 12159 (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 86216 (raises risk) · Drug's FDA history
• Maximum age: 45 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 10 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects NCT05519514 · started 2021 · scored riskier than 0% of active trials completed
• A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block NCT04494321 · started 2017 · scored riskier than 0% of active trials completed
• Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France) NCT04854538 · started 2020 · scored riskier than 0% of active trials completed
• A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade NCT04124094 · started 2019 · scored riskier than 0% of active trials completed
• India Dexamethasone and Betamethasone NCT03668860 · started 2018 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.